国药科技股份(08156)发布中期业绩，股东应占亏损287.6万港元 同比盈转亏
国药科技股份(08156)发布截至2023年12月31日止6个月中期业绩，该集团取得收入1884.4万港元，同比增加25.42%;公司股权持有人应占亏损287.6万港元，去年同期则溢利1540.8万港元;每股基本亏损1.57港仙。
于回顾期间，集团持续加快于大健康产业上的布局，透过于中国境内成立子公司，就发展分销中成药物及健康产品完成相关布局，为集团提供新的收入来源及业务发展方向，集团于“互联网+”服务项下的供应链业务上持续发展并于本回顾期间取得稳定发展。集团亦正与各行业运营方及产品供应方商讨合作模式，透过集团于“互联网+”业务上的经验，为各行业运营方提供增值服务。藉此为集团在“互联网+”业务上带来的新机遇及标志着加快推进集团于“互联网+”业务上应用于不同的商业模式中。
Reprinted from 引领外汇网，the copyright all reserved by the original author.
Disclaimer: The content above represents only the views of the author or guest. It does not represent any views or positions of FOLLOWME and does not mean that FOLLOWME agrees with its statement or description, nor does it constitute any investment advice. For all actions taken by visitors based on information provided by the FOLLOWME community, the community does not assume any form of liability unless otherwise expressly promised in writing.
FOLLOWME Trading Community Website: https://www.followme.com
Hot
No comment on record. Start new comment.